ArticleJournal of nanobiotechnology2025
A smartphone-colorimetric dual-mode diagnosis method for breast cancer detection of BRCA-1 gene base on silver plated substrate and catalytic hairpin assembly amplification.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer is the most prevalent malignancy among women worldwide. With rapid societal development, there has been a consistent increase in breast cancer incidence rates annually, accompanied by a progressively younger age of onset. Consequently, there is an urgent need to develop a rapid, sensitive, and highly specific approach for the identification of BRCA-1. In this study, we successfully devised a heterogeneous system based on G-quadruplex DNAzyme for label-free and enzyme-free visual detection of BRCA-1. Moreover, the distinctive G-quadruplex (G4) DNAzyme ensures precise and accurate detection through enzyme-free amplification, colorimetric detection, and catalytic hairpin assembly mechanisms. The utilization of this heterogeneous system effectively minimizes background interference while exhibiting exceptional sensitivity and accuracy with an impressive detection limit as low as 0.6 pM. Furthermore, real sample analysis yielded an area under the ROC curve value of 0.9825 which demonstrates its robust performance for early screening purposes when integrated with smartphone-assisted analysis, thus showcasing its potential for widespread application in early breast cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.